JP2002503477A5 - - Google Patents

Download PDF

Info

Publication number
JP2002503477A5
JP2002503477A5 JP2000531578A JP2000531578A JP2002503477A5 JP 2002503477 A5 JP2002503477 A5 JP 2002503477A5 JP 2000531578 A JP2000531578 A JP 2000531578A JP 2000531578 A JP2000531578 A JP 2000531578A JP 2002503477 A5 JP2002503477 A5 JP 2002503477A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
viral
virus
vector
virus particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2000531578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002503477A (ja
Filing date
Publication date
Priority claimed from GBGB9803351.7A external-priority patent/GB9803351D0/en
Application filed filed Critical
Publication of JP2002503477A publication Critical patent/JP2002503477A/ja
Publication of JP2002503477A5 publication Critical patent/JP2002503477A5/ja
Ceased legal-status Critical Current

Links

JP2000531578A 1998-02-17 1999-02-17 抗ウイルスベクター Ceased JP2002503477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9803351.7 1998-02-17
GBGB9803351.7A GB9803351D0 (en) 1998-02-17 1998-02-17 Anti-viral vectors
PCT/GB1999/000325 WO1999041397A1 (en) 1998-02-17 1999-02-17 Anti-viral vectors

Publications (2)

Publication Number Publication Date
JP2002503477A JP2002503477A (ja) 2002-02-05
JP2002503477A5 true JP2002503477A5 (enExample) 2006-06-08

Family

ID=10827139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000531578A Ceased JP2002503477A (ja) 1998-02-17 1999-02-17 抗ウイルスベクター

Country Status (10)

Country Link
US (2) US6541248B1 (enExample)
EP (2) EP1790658A3 (enExample)
JP (1) JP2002503477A (enExample)
CN (1) CN1297486A (enExample)
AT (1) ATE358732T1 (enExample)
AU (1) AU757284B2 (enExample)
CA (1) CA2321097A1 (enExample)
DE (1) DE69935714T2 (enExample)
GB (1) GB9803351D0 (enExample)
WO (1) WO1999041397A1 (enExample)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
DE50015096D1 (de) * 1999-11-16 2008-05-21 Geneart Ag Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US8202846B2 (en) * 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
ATE414794T1 (de) * 2000-09-01 2008-12-15 Gen Probe Inc Amplifizierung von hiv-1 sequenzen zur detektion von sequenzen, die mit wirkstoff-resistenz mutationen einhergehen
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
WO2002024897A2 (en) * 2000-09-22 2002-03-28 Virxsys Conditionally replicating viral vectors and their use
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
IL157087A0 (en) 2001-01-25 2004-02-08 Virxsys Corp A method for identifying a function of a gene sequence
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
ES2411981T3 (es) * 2002-02-01 2013-07-09 Oxford Biomedica (Uk) Limited Vector lentivírico
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
US20090088625A1 (en) * 2007-10-01 2009-04-02 Kenneth Oosting Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery
US9169491B2 (en) 2008-06-18 2015-10-27 Oxford Biomedica (Uk) Limited Virus purification
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
WO2014093965A1 (en) * 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
SG11201701309SA (en) 2014-09-15 2017-04-27 Molmed Spa Chimeric antigen receptors
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
CA3254091A1 (en) * 2014-12-16 2025-10-27 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
PL3380620T3 (pl) 2015-11-23 2024-11-12 Novartis Ag Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
GB201604146D0 (en) 2016-03-10 2016-04-27 Nightstarx Ltd Prenylation assay
EP3318285A1 (en) 2016-11-08 2018-05-09 Oxford University Innovation Limited Treatment of eye disease
EP3548618A1 (en) 2016-12-01 2019-10-09 Nestec S.A. Methods of modulating fam46a
EP3375876A1 (en) 2017-03-13 2018-09-19 Evonetix Ltd Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
JP2020515551A (ja) 2017-03-31 2020-05-28 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ank1を調節する方法
SI3612624T1 (sl) 2017-04-21 2025-03-31 Ospedale San Raffaele S.R.L. Genska terapija
BR112019022321A2 (pt) 2017-04-24 2020-05-26 Ospedale San Raffaele S.R.L. Tcr e peptídeos
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
SG11202003462SA (en) 2017-10-17 2020-05-28 Nightstarx Ltd Prenylation assay
EP3713580A1 (en) 2017-11-21 2020-09-30 Société des Produits Nestlé S.A. Methods of modulating alk
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
IL278016B2 (en) 2018-04-18 2025-03-01 Ucl Business Ltd Method for Enhancing the Suppressive Properties of Treg Cells
BR112020023015A2 (pt) 2018-05-15 2021-02-17 Flagship Pioneering Innovations V, Inc. composições de fusossoma e usos das mesmas
WO2019219308A1 (en) 2018-05-17 2019-11-21 Societe Des Produits Nestle S.A. Methods of modulating nkx6.3
WO2019229109A1 (en) 2018-05-30 2019-12-05 Glycostem Therapeutics B.V. Car nk cells
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
GB201817821D0 (en) 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
JP2022507453A (ja) 2018-11-14 2022-01-18 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド T細胞送達のためのフソソーム組成物
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
EP3898947A1 (en) 2018-12-19 2021-10-27 King's College London Immunotherapeutic methods and compositions
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
KR20220034719A (ko) 2019-03-10 2022-03-18 시오 진 테라피스 인코포레이티드 파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
GB201912515D0 (en) 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
CA3152525A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
KR20220139911A (ko) 2020-02-13 2022-10-17 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터의 생산
GB2609103A (en) 2020-02-25 2023-01-25 Quell Therapeutics Ltd Chimeric receptors for use in engineered cells
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4118217A1 (en) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentiviral vectors
CN116096866A (zh) 2020-03-31 2023-05-09 萨那生物科技公司 靶向脂质颗粒及其组合物和用途
WO2021222222A1 (en) 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
WO2022047316A1 (en) 2020-08-28 2022-03-03 Sana Biotechnology, Inc. Modified anti-viral binding agents
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
US20240052015A1 (en) 2020-12-23 2024-02-15 Quell Therapeutics Limited Inducible signalling protein
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
JP2024506751A (ja) 2021-02-01 2024-02-14 イプシレン バイオ エス.アール.エル. 遺伝子サイレンシング
US20240101623A1 (en) 2021-02-15 2024-03-28 Ospedale San Raffaele S.R.L. Epigenetic silencing for treatment of cancer
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
IL308356A (en) 2021-05-12 2024-01-01 Fond Telethon Vector system
US20240254168A1 (en) 2021-05-28 2024-08-01 Sana Biotechnology, Inc. LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USES
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
US20250000966A1 (en) * 2021-10-13 2025-01-02 The Cleveland Clinic Foundation Mrna vaccine design via the alteration of codon usage
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4209511A1 (en) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies amd chimeric antigen receptors
US20250064853A1 (en) 2022-01-05 2025-02-27 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
EP4473097A1 (en) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4269426A1 (en) 2022-04-29 2023-11-01 Ospedale San Raffaele S.r.l. Gene therapy
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
CA3261363A1 (en) 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. TRANSGENIC CASSETTES
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4615492A1 (en) 2022-11-08 2025-09-17 Ospedale San Raffaele S.r.l. Polynucleotide and vector
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4651887A1 (en) 2023-01-16 2025-11-26 Ospedale San Raffaele S.r.l. T-cell receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
WO2024165859A1 (en) 2023-02-07 2024-08-15 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194223A2 (en) 2023-03-17 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
AU2024241563A1 (en) 2023-03-22 2025-10-09 Consiglio Nazionale Delle Ricerche Gene therapy
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
GB202307366D0 (en) 2023-05-17 2023-06-28 Ospedale San Raffaele Srl Vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2024261480A1 (en) 2023-06-21 2024-12-26 Quell Therapeutics Limited Constitutive cytokine receptors
WO2025003481A2 (en) 2023-06-28 2025-01-02 Ospedale San Raffaele S.R.L. T-cell receptors
WO2025032194A1 (en) 2023-08-08 2025-02-13 Ospedale San Raffaele S.R.L. T-cell receptors
GB202316264D0 (en) 2023-10-24 2023-12-06 Ospendale San Raffaele S R L Gene therapy
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025109189A1 (en) 2023-11-24 2025-05-30 Ospedale San Raffaele S.R.L. Engineered regulatory t cells and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038247T5 (es) 1987-07-29 2009-11-06 Basf Lacke + Farben Ag Baños acuosos de electroinmersion que contienen resinas sinteticas precipitables catodicamente y procedimiento para el recubrimiento de substratos conductores electricos.
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
DE69635052T2 (de) * 1995-05-26 2006-06-08 Asahi Kasei Pharma Corp. Verfahren zur Bestimmung von Antikörpern, die die reverse Transkriptase-Aktivitaet hemmen
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1380650B1 (en) * 1995-11-28 2010-01-20 The Johns Hopkins University School Of Medicine Conditionally replicating viral vectors and their use
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
EP0880594B1 (en) 1996-01-23 2002-10-23 Oxford Biomedica (UK) Limited Retroviral vector and its use in gene therapy
IL125547A0 (en) 1996-02-22 1999-03-12 Merck & Co Inc Synthetic hiv genes
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CZ137399A3 (cs) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
CN1252075A (zh) * 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
KR100556864B1 (ko) * 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
JP4578678B2 (ja) 1997-12-22 2010-11-10 オックスフォード バイオメディカ(ユーケー)リミテッド ウマ伝染性貧血ウイルス(eiav)系
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO2000015819A1 (en) 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
WO2000065076A2 (en) 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
GB9923558D0 (en) 1999-10-05 1999-12-08 Oxford Biomedica Ltd Producer cell

Similar Documents

Publication Publication Date Title
JP2002503477A5 (enExample)
JP2004508808A5 (enExample)
Maurer et al. Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus
US5886166A (en) Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
Haas et al. Codon usage limitation in the expression of HIV-1 envelope glycoprotein
Kato et al. The entire nucleotide sequence of baboon endogenous virus DNA: a chimeric genome structure of murine type C and simian type D retroviruses
JP2019514414A (ja) ゲノム工学システムのカプシド形成のための粒子
Li et al. Sequence and insertion sites of murine melanoma-associated retrovirus
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
JP2002538829A (ja) 抗ウイルスベクター
JPWO2019152692A5 (enExample)
JP2004509601A5 (enExample)
CN116554349A (zh) 嵌合病毒包膜糖蛋白及包含其的载体
US20240175053A1 (en) Factor VIII Molecules and Their Use
EP2240508A1 (en) Secretable hiv entry inhibitory peptides for therapy of hiv infection
JPH10507628A (ja) 非自己不活化性の発現標的化レトロウイルスベクタ
Pérot et al. From viruses to genes: syncytins
CA2450548C (en) Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
JP3453611B2 (ja) ハイブリッド形態の新規可溶性、非開裂性gp160変異体
WO2025153043A1 (zh) 用于递送核酸和蛋白质的类病毒样蛋白颗粒及其制备方法
Hughes et al. Morphogenic capabilities of human immunodeficiency virus type 1 gag and gag-pol proteins in insect cells
Laco et al. Analysis of the proteolytic processing and activation of the rice tungro bacilliform virus reverse transcriptase
WO1993005147A1 (en) Defective interfering hiv particles with chimeric cd4-env
WO2012118092A1 (ja) 融合タンパク質
JP2008521384A (ja) コロナウィルス様粒子をコードする発現ベクター